These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 10779027)
21. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Findik S; Erkan ML; Selçuk MB; Albayrak S; Atici AG; Doru F Respiration; 2002; 69(5):440-4. PubMed ID: 12232452 [TBL] [Abstract][Full Text] [Related]
22. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD. Israel EN; Thomas CA; Mastropietro CW Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713 [TBL] [Abstract][Full Text] [Related]
23. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review. Ho SH; Wu JK; Hamilton DP; Dix DB; Wadsworth LD J Pediatr Hematol Oncol; 2004 Sep; 26(9):561-6. PubMed ID: 15342982 [TBL] [Abstract][Full Text] [Related]
24. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Holzheimer RG Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403 [TBL] [Abstract][Full Text] [Related]
25. Increased Enoxaparin Dosing Requirements for Treatment of Deep Vein Thrombosis in a Severely Burned Patient: Case Report and Literature Review. Yost RJ; Haan BJ; Mangan KC Pharmacotherapy; 2018 Nov; 38(11):e82-e86. PubMed ID: 30129107 [TBL] [Abstract][Full Text] [Related]
26. Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin or unfractionated heparin. Griffin JW; Hopkinson WJ; Lassen MR; Thethi I; Litinas E; Fareed J Clin Appl Thromb Hemost; 2011; 17(6):567-71. PubMed ID: 22345625 [TBL] [Abstract][Full Text] [Related]
27. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867 [TBL] [Abstract][Full Text] [Related]
28. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Bara L; Planes A; Samama MM Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702 [TBL] [Abstract][Full Text] [Related]
32. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. Antman EM Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group. Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025 [TBL] [Abstract][Full Text] [Related]
34. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. Gibson JL; Ekevall K; Walker I; Greer IA Br J Obstet Gynaecol; 1998 Jul; 105(7):795-7. PubMed ID: 9692422 [TBL] [Abstract][Full Text] [Related]
35. Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. Turpie AG; Mason JA Expert Opin Pharmacother; 2002 May; 3(5):575-98. PubMed ID: 11996636 [TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080 [TBL] [Abstract][Full Text] [Related]
37. Factor Xa inactivation in acute coronary syndrome. Barantke M; Bonnemeier H Curr Pharm Des; 2008; 14(12):1186-90. PubMed ID: 18473865 [TBL] [Abstract][Full Text] [Related]
38. Spotlight on enoxaparin in ST-segment elevation myocardial infarction. Carter NJ; McCormack PL; Plosker GL BioDrugs; 2008; 22(5):343-5. PubMed ID: 18778116 [TBL] [Abstract][Full Text] [Related]
39. Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study. Miranda S; Le Cam-Duchez V; Benichou J; Donnadieu N; Barbay V; Le Besnerais M; Delmas FX; Cuvelier A; Lévesque H; Benhamou Y; Armengol G Thromb Res; 2017 Jul; 155():1-5. PubMed ID: 28460259 [TBL] [Abstract][Full Text] [Related]
40. Enoxaparin in acute coronary syndromes. Lee S; Gibson CM Expert Rev Cardiovasc Ther; 2007 May; 5(3):387-99. PubMed ID: 17489664 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]